)
Edge1 May 2026
Making the Marlboro Man
The story of Marlboro's transformation from a women's cigarette to a global icon: one of the most effective brand repositionings in history.
Pharmala Biotech
Pharmala Biotech (MDMA) investor relations material
Pharmala Biotech Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary21 Apr, 2026
Executive summary
Focused on research, development, and manufacturing of MDXX class molecules, including MDMA, with a growing operational presence in Australia and the U.S.
Only company currently provisioning clinical-grade MDMA for patient treatments outside of clinical trials.
Leadership change announced with the departure of the Chief Commercial Officer by July 2026.
Financial highlights
Revenues for Q2 2026 were $220,584, up from $145,657 in Q2 2025; six-month revenues reached $487,024, up from $202,954 year-over-year.
Net loss for Q2 2026 was $337,696, a significant improvement from $810,766 in Q2 2025; six-month net loss was $747,391, down from $1,289,875 year-over-year.
Customer deposits increased by $310,719 in Q2, with $181,492 recognized as revenue.
Cash used in operating activities for the six months was $366,396, down from $491,721 in the prior year period.
Outlook and guidance
Management expects operational know-how and regulatory relationships to drive value as psychedelics move toward commercialization globally.
Forward-looking statements caution that actual results may differ due to risks and uncertainties.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Pharmala Biotech
- Revenue surged 10x year-over-year, with key patent and joint venture milestones achieved.MDMA
Q3 20245 May 2026 - Revenue up 95% with strong MDMA sales and new funding; distribution and U.S. growth drive outlook.MDMAQ1 20255 May 2026
- MDMA shipments and revenue rose, with operational gains and higher expenses from expansion.MDMAQ3 20255 May 2026
- Customer deposits and clinical trial pipeline grew, driven by Australian regulatory approvals.MDMAQ1 20265 May 2026
- Revenue surged 95% with improved EBITDA and a $1.56M private placement completed.MDMAQ4 202429 Dec 2025
- Customer deposits and clinical trial pipeline surged, fueled by Australian market expansion.MDMAQ4 202529 Dec 2025
- Revenue surged 95% year-over-year, with operational gains and expanded distribution.MDMAQ2 202529 Dec 2025
- MDMA therapy delivers rapid PTSD remission and global expansion, backed by innovation and strong IP.MDMASmall Cap Growth Virtual Investor Conference 202520 Oct 2025
Next Pharmala Biotech earnings date
Q3 202624 Jul, 2026
Pharmala Biotech
Next Pharmala Biotech earnings date
Q3 202624 Jul, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage